Genovis AB (publ.) (STO:GENO)
Sweden · Delayed Price · Currency is SEK 19.62
-0.83 (-4.06%)
Feb 10, 2026, 5:24 PM CET
Genovis AB (publ.) Revenue
Genovis AB (publ.) had revenue of 27.74M SEK in the quarter ending September 30, 2025, a decrease of -16.61%. This brings the company's revenue in the last twelve months to 117.66M, down -10.31% year-over-year. In the year 2024, Genovis AB (publ.) had annual revenue of 131.32M, down -17.44%.
Revenue (ttm)
117.66M
Revenue Growth
-10.31%
P/S Ratio
11.48
Revenue / Employee
3.27M
Employees
36
Market Cap
1.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131.32M | -27.75M | -17.44% |
| Dec 31, 2023 | 159.07M | 55.51M | 53.60% |
| Dec 31, 2022 | 103.56M | 9.89M | 10.55% |
| Dec 31, 2021 | 93.68M | 32.65M | 53.49% |
| Dec 31, 2020 | 61.03M | 480.58K | 0.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioInvent International AB | 244.85M |
| Oncopeptides AB | 62.47M |
| Egetis Therapeutics AB | 55.40M |
| Vicore Pharma Holding AB | 8.50M |
| Xspray Pharma AB | 3.81M |
| Flerie AB | 2.80M |
| Diamyd Medical AB | 349.00K |
| Infant Bacterial Therapeutics AB | -1.00K |
Genovis AB (publ.) News
- 1 year ago - Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus